[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"human-papillomavirus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:human-papillomavirus-infection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,41,85,109,135,165,196,222,246,275,304,332],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100647308","a-scientific-evaluation-of-one-or-two-doses-of-a-vaccine-against-human-papillomavirus-long-term-follow-up-of-gardasil9-recipients-in-the-escuddo-study-estudio-de-comparacin-de-una-y-dos-dosis-de-vacunas-contra-el-virus-de-papiloma-humano-vph-100647308",false,"NCT07706673","ESCUDDO Long Term Follow Up","A Scientific Evaluation of One or Two Doses of a Vaccine Against Human Papillomavirus: Long Term Follow Up of Gardasil9 Recipients in the ESCUDDO Study (\"Estudio de Comparación de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)\")","ESCUDDO LTFU","Inclusion Criteria:\n\n* \\* Participation in ESCUDDO base study\n\n  * Randomization (excluding the two participants who had major protocol deviations in the ESCUDDO base study) to the Gardasil9 1- and 2-dose arms\n  * A signed informed consent form for ESCUDDO LTFU.\n  * Opportunity to complete three total study visits\n  * LTFU Survey group:\n\n    * We will match the current ages of ESCUDDO LTFU trial participants when they attend their 9.5-year study visit (21 to 26 years of age)\n\nExclusion Criteria:\n\n* \\* Enrollment cannot occur beyond her 10 year study visit\n\n  * LTFU Survey group:\n\n    * They report they are pregnant;\n    * They report being vaccinated against HPV;\n    * The qualified healthcare personnel determining eligibility, in agreement with principal investigator, considers a reason that precludes participation; or\n    * They do not have an identification document",true,"FEMALE","18 Years",{"count":21,"type":22},9700,"ESTIMATED","OBSERVATIONAL","This study evaluates the long term protection provided by either one or two doses of the 9vHPV vaccine for participants who were part of the ESCUDDO study.",[26,27],"Human Papillomavirus Infection","Human Papillomavirus-Related Malignant Neoplasm","NOT_YET_RECRUITING","2026-08-19",{"date":31,"type":32},"2026-08-20","ACTUAL",{"date":34,"type":22},"2026-09-17",{"date":36,"type":22},"2031-01-15",{"name":38,"class":39},"National Cancer Institute (NCI)","NIH",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100651610","papilozumib-vaginal-gel-for-exocervical-mucosal-restoration-in-women-with-hpv-100651610","NCT07762209","Papilozumib Vaginal Gel for Exocervical Mucosal Restoration in Women With HPV","Exploratory, Randomized, Multicenter, Open-Label, Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy of Papilozumib® Vaginal Gel in the Restoration of the Exocervical Mucosa","Inclusion Criteria:\n\n* Female participant aged 30 to 50 years, inclusive.\n* Able to read and understand the participant information sheet and informed consent form.\n* Willing to participate and able to provide written informed consent.\n* Normal cervical cytology or cervical cytology showing atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), or atypical glandular cells (AGC), with corresponding colposcopic findings at baseline.\n* Cervical cytology obtained no more than 3 months before the baseline\u002Frandomization visit.\n* Positive test for human papillomavirus (HPV) by polymerase chain reaction (PCR) at baseline.\n* HPV PCR test obtained no more than 3 months before the baseline\u002Frandomization visit.\n* Exocervical mucosal restoration score of 3 or lower on the 5-point colposcopic scale at baseline.\n* Baseline colposcopy performed no more than 3 months before randomization; the score may be determined from previously recorded images when available in the medical record.\n* Considered by the investigator able to follow the study instructions, attend the required visits, and complete the study assessments.\n\nExclusion Criteria:\n\n* Clinically relevant immune-system disorder, autoimmune disease, or current treatment with immunosuppressive medication.\n* Systemic or local treatment with antibiotics, antifungal agents, or another treatment that may alter the microbiota within 4 weeks before baseline\u002Frandomization.\n* Undiagnosed abnormal genital bleeding during the 6 months before screening.\n* Symptomatic vulvovaginal infection.\n* Surgical cervical excision within the previous year, cervical conization within the previous 6 months, or previous total hysterectomy.\n* Previous gynecological cancer.\n* Current participation in another clinical study or participation in another clinical study within 4 weeks before screening.\n* Planned surgery that could prevent adherence to the study treatment schedule.\n* Use of vaginal contraceptives or other vaginal hormonal treatments.\n* Contraindication to the vaginal gel or known allergy to any of its components.\n* Pregnant, suspected to be pregnant, breastfeeding, or of childbearing potential and not using an effective contraceptive method.","30 Years","50 Years",{"count":51,"type":22},81,"INTERVENTIONAL",[54],"NA","This randomized, open-label, multicenter clinical study is designed to evaluate Papilozumib® vaginal gel in women aged 30 to 50 years who test positive for human papillomavirus (HPV) and present with either normal cervical cytology or cytological findings of atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), or atypical glandular cells (AGC), accompanied by corresponding colposcopic findings.\n\nEighty-one participants will be randomly assigned in equal groups to receive either Papilozumib® vaginal gel, Papilozumib® vaginal gel plus an oral supplement, or standard clinical care without study treatment. All participants will be followed for six months.\n\nThe primary objective is to assess exocervical mucosa restoration 30 days after treatment initiation using a 5-point colposcopic scale. Additional assessments include cervical cytology, HPV clearance, vaginal health, treatment adherence, satisfaction, tolerability, safety, and exploratory analyses of the vaginal and intestinal microbiota.",[26,57],"Human Papillomavirus Infections",[59,60,61,62,63,64,65,66,67,68,69,70,71,72,73],"Human Papillomavirus","HPV","Exocervical Mucosal Restoration","Cervical Cytology","ASC-US","Low-Grade Squamous Intraepithelial Lesion","LSIL","Atypical Glandular Cells","AGC","HPV Clearance","Vaginal Health","Vaginal Microbiota","Gut Microbiota","Papilozumib","Vaginal Gel","2026-08-07",{"date":76,"type":32},"2026-08-13",{"date":78,"type":22},"2027-07",{"date":80,"type":22},"2027-12",{"name":82,"class":83},"Hifas da Terra S.L.","INDUSTRY",6,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":17,"sex":18,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":52,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100614579","self-collection-for-hpv-testing-to-improve-cervical-cancer-prevention-ship-trial-lmi-001-a-s04-100614579","NCT07281430","Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)","NCI Cervical Cancer 'Last Mile' Initiative 'Self-Collection for HPV Testing to Improve Cervical Cancer Prevention' (SHIP) Trial LMI-001-A-S04","Inclusion Criteria:\n\n* Willingness and ability to provide a documented informed consent\n* Is 25 years or older\n* Has an intact cervix\n* Has had a referral for colposcopy in which routine cervical cancer screening has included positive HPV testing (HPV primary screening, co-testing, or atypical squamous cells of undetermined significance \\[ASC-US\\] cytology triage) or abnormal cytology performed within the past 12 months preceding the referral visit, and\u002For for cervical excisional procedure\n* Willing and able to undergo colposcopy, and if clinically indicated for SOC purposes, a biopsy, endocervical curettage, and\u002For a cervical excisional procedure, as applicable\n\nExclusion Criteria:\n\n* Is pregnant when presenting for the referral visit or gave birth within the past 3 months\n* Has a known history of excisional or ablative therapy to the cervix (e.g., loop electrosurgical excision procedure \\[LEEP\\], cone biopsy, cervical laser surgery, cryotherapy, thermal ablation) in the last 12 months prior to the referral visit\n* Has had a complete or partial hysterectomy, either supracervical or involving removal of the cervix, via self-report or confirmation via medical records\n* Known medical conditions that, in the opinion of the investigator, preclude study participation\n* Previous participation in the SHIP Trial or another cervical cancer screening study within the past 12 months. Participation is defined as completing the self-collection\n* Is experiencing unusual bleeding or pelvic pain","25 Years",{"count":94,"type":22},500,[54],"This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and\u002For cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. HPV is known to cause a variety of cancers including cervical cancer. Even though there are ways to detect cervical cancer, many individuals are not diagnosed. Over half of all new cervical cancer cases are among those who have either never been screened or who are not screened enough. The low screening numbers show more testing needs to be done. Without appropriate screening and care, preventable precancer may turn into cancer. A new way to detect cervical cancer is to have individuals collect their own sample for HPV testing to know their risk for cervical cancer. This may give individuals more flexibility and comfort having the ability to collect samples themselves, compared to a doctor performing a speculum examination and collecting the samples in a clinic. Information gathered from this study compares clinical accuracy of HPV testing on self-collected vaginal samples versus cervical samples collected by clinician.\n\nThe Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial is part of the National Cancer Institute (NCI)'s Cervical Cancer 'Last Mile' Initiative, a public private partnership that seeks to increase access to cervical cancer screening. The SHIP Trial focuses on developing clinical evidence to inform the US Food and Drug Administration (FDA)'s regulatory reviews of self-collection approaches as alternative sample collection approaches for cervical cancer screening. Several industry partner-specific self-collection device and assay combinations will be non-competitively and independently evaluated with a similar study design framework to inform pre-approval and\u002For post-approval regulatory requirements.",[98,26],"Cervical Carcinoma","RECRUITING","2026-07-30",{"date":102,"type":32},"2026-07-31",{"date":104,"type":32},"2025-11-24",{"date":106,"type":22},"2027-06-30",{"name":38,"class":39},18,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":115,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":52,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":40},"100562077","investigating-facilitator-driven-multi-level-implementation-strategies-in-federally-qualified-health-centers-to-improve-provider-recommendation-and-hpv-vaccination-rates-among-latinoa-adolescents-100562077","NCT06598475","Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino\u002Fa Adolescents","Inclusion Criteria:\n\n* FQHC's with less than 60% HPV vaccine initiation rate for 11-12 year old adolescents overall at their practice sites\n* FQHC's that have family medicine and\u002For pediatric practices\n* a total adolescent patient population at least 50% Latino\n* be willing for Health Care Provider (HCP) and staff members to receive education, training, and support; complete standardized measurement, and agree to randomization.\n* Providers, aged 18 and over, employed at each FQHC (4 staff per practice)\n* Staff, aged 18 and over, employed at each FQHC (5 staff per practice)\n* Implementation team members (i.e., administrative designee, health care providers, immunization navigators, and other staff), aged 18 and over, employed at each FQHC (4 members per practice)\n* Parents (aged 18 and over) of patients ages 11-17 seeking care at each FQHC (25 per practice).\n\nExclusion Criteria:\n\n-FQHCs that participated in the pilot study were excluded.","ALL","11 Years","17 Years",{"count":119,"type":22},225,[54],"The purpose of this study is to determine the provider- and practice-level characteristics that influence the impact of implementation strategies guided by practice facilitation in each clinical practice, to test whether the facilitator-driven provider- and practice-level implementation strategies increase provider recommendations and Human Papilloma Virus (HPV) vaccination rates and to evaluate implementation and future sustainability of the facilitator-driven implementation strategies across nine clinical practice sites",[26],[124],"HPV vaccination","2026-04-28",{"date":127,"type":32},"2026-05-04",{"date":129,"type":32},"2025-03-13",{"date":131,"type":22},"2028-08-01",{"name":133,"class":134},"The University of Texas Health Science Center, Houston","OTHER",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":17,"sex":18,"minAge":92,"maxAge":49,"enrollmentInfo":142,"targetDuration":4,"studyType":52,"phases":144,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100635232","digital-telecytology-for-triage-of-hpv-positive-women-in-cameroon-100635232","NCT07550010","Digital Telecytology for Triage of HPV-Positive Women in Cameroon","Evaluation of Digital Cytology for the Triage of HPV-positive Women in a Same-day \"Test-triage-treat\" Cervical Cancer Screening Strategy in Cameroon","Inclusion Criteria:\n\n* HIV-negative women aged 30-49 and HIV-positive women aged 25-49 years old\n* Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF).\n\nExclusion Criteria:\n\n* Pregnancy at the time of screening\n* Previous hysterectomy\n* Known cervical cancer\n* Symptoms of cervical cancer (e.g. metrorrhagia, known pelvic mass)\n* Conditions that can interfere with visualization of the cervix\n* Severe pre-existing medical conditions (e.g. advanced cancer, terminal renal failure)\n* Women who are not able to comply with the study protocol.",{"count":143,"type":22},1800,[54],"This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon. Women aged 30-49 years (or 25-49 years if HIV-positive) will undergo primary HPV testing using the GeneXpert system. HPV-positive women will be managed according to an extended HPV genotyping-based algorithm, including immediate treatment, telecytology triage, or follow-up. Histological assessment serves as the reference standard for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Secondary objectives include evaluation of AI-assisted telecytology and visual inspection with acetic acid (VIA), as well as the acceptability of screening and treatment strategies among women and healthcare providers. The study aims to generate evidence to support scalable, WHO-recommended test-triage-treat approaches in low-resource settings",[26,147,148],"Cervical Intraepithelial Neoplasia Grade 2 (CIN2)","Cervical Cancer Screening Methods",[150,151,152,153,154],"HPV self-sampling","Telecytology","Artificial intelligence","Extended HPV genotyping","Low-resource settings","2026-04-17",{"date":157,"type":32},"2026-04-24",{"date":159,"type":32},"2025-09-08",{"date":161,"type":22},"2027-09-08",{"name":163,"class":134},"University Hospital, Geneva",2,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":17,"sex":18,"minAge":48,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":52,"phases":176,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":40},"100379879","self-sampling-for-non-attenders-to-cervical-cancer-screening-100379879","NCT04226313","Self-sampling for Non-attenders to Cervical Cancer Screening","Cervical Cancer Prevention Using Self-sampling and Human Papillomavirus Detection","KOPRETINA","Inclusion Criteria:\n\n* Women with age 30-65 years; for arm A women \\> 65 years are allowed\n* Women live in the Czech Republic.\n* Women who have not participate in cervical cancer screening program in the Czech Republic for at least 3 years (Arm B and C).\n* Women with completed informed consent.\n* Women capable of self-sampling of cervicovaginal swab.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Women with no sexual intercourse experience.\n* Women after hysterectomy including cervix.","65 Years",{"count":175,"type":22},15000,[54],"The trial will evaluate whether self-sampling and human papillomavirus (HPV) testing may increase cervical cancer screening attendance among under-screened women in Czech Republic. Different ways of offering self-sampling device will be evaluated.",[179,180,26],"Cervical Cancer","Cervical Dysplasia",[182,60,183,184,185,186],"human papillomavirus","self-sampling","cervicovaginal swab","cervical cancer screening","non-attendance","2026-03-19",{"date":189,"type":32},"2026-03-23",{"date":191,"type":32},"2019-09-23",{"date":193,"type":22},"2026-12-01",{"name":195,"class":134},"The Institute of Molecular and Translational Medicine, Czech Republic",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":52,"phases":207,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":40},"100628452","point-of-care---triage-and-treatment-for-cervical-pre-cancer-100628452","NCT07461818","Point of Care - Triage and Treatment for Cervical Pre-cancer","POINT of CARE - Providing an Innovative New Triage and Treatment Strategy for Cervical Cancer Screening Efficiency","POC","Inclusion Criteria:\n\n* Women aged 30-49 years\n* Non-pregnant (determined by urine pregnancy test)\n* HPV-positive per Ministry of Health (MOH) records\n* Willing to undergo colposcopy and biopsies\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Plans to become pregnant during the study\n* History of LEEP or cervical ablation procedure in the past 5 years\n* History of total hysterectomy (verified by medical record or pelvic evaluation)\n* History of cervical cancer\n* Unable or unwilling to provide a permanent and reliable address\n* Unable or unwilling to provide informed consent","49 Years",{"count":206,"type":22},5000,[54],"This study evaluates a modified two-probe thermal ablation protocol using the IRIS™ device and retrospectively assesses an AI-based Automated Visual Evaluation (AVE) triage algorithm among HPV-positive women in El Salvador. The primary objective is to estimate 1-year cure rates of CIN2+ following treatment. A secondary objective is to evaluate the diagnostic performance of AVE compared with histopathology.",[210,211,26],"Cervical Precancer","Cervical Intraepithelial Neoplasia",[179],"2026-03-09",{"date":215,"type":32},"2026-03-11",{"date":217,"type":22},"2026-03",{"date":219,"type":22},"2029-08",{"name":221,"class":134},"Basic Health International, Inc.",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":115,"minAge":19,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":245,"locationsCount":40},"100498769","role-of-liquid-biopsies-in-hpv-associated-cancer-treatment-monitoring-100498769","NCT05774561","Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring","Liquid Biopsies - a Possible Tool for Treatment Monitoring and Early Recurrence Detection in HPV-associated Diseases","Inclusion Criteria:\n\nWomen diagnosed with CC\u002FHSIL. Men and women diagnosed with OPC. Patients must agree with study enrollment and must sign study informed consent.\n\nExclusion Criteria:\n\nNo exclusion criteria are set.","99 Years",{"count":231,"type":22},480,"This trial will evaluate the possible benefits and the performance of liquid biopsies in HPV-associated cancer treatment monitoring. This study aims to find a combination of an adequately sensitive and specific sampling method and biomarkers for early risk stratification of disease recurrence.",[179,180,234,26],"Oropharyngeal Cancer",[182,60,236,184,237,238],"liquid biopsies","cervical cancer","oropharyngeal cancer","2026-02-10",{"date":241,"type":32},"2026-02-12",{"date":243,"type":32},"2022-06-01",{"date":193,"type":22},{"name":195,"class":134},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":60,"eligibilityCriteria":252,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":52,"phases":256,"briefSummary":257,"conditions":258,"keywords":259,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":40},"100600459","the-effect-of-health-belief-model-based-education-and-motivational-interviewing-on-hpv-human-papilloma-virus-knowledge-and-vaccine-awareness-in-women-100600459","NCT07097766","The Effect of Health Belief Model-Based Education and Motivational Interviewing on HPV (Human Papilloma Virus) Knowledge and Vaccine Awareness in Women","The Effect of Health Belief Model-Based Education and Motivational Interviewing on Human Papillomavirus (HPV) Infection Knowledge Level and HPV Vaccine Awareness Among Women","Inclusion Criteria:\n\n* Women aged between 18-45 years\n\nVoluntary participation and providing informed consent\n\nNot previously vaccinated against HPV\n\nAbility to attend all three educational and motivational interview sessions\n\nLiteracy sufficient to complete study questionnaires\n\nExclusion Criteria:\n\n* Women under 18 or over 45 years old\n\nPrior HPV vaccination\n\nCognitive or psychiatric conditions that hinder participation\n\nCurrently participating in another HPV-related education or intervention study\n\nInability to attend all sessions of the intervention program","45 Years",{"count":255,"type":22},60,[54],"This study aims to evaluate the effect of an educational intervention based on the Health Belief Model (HBM) combined with motivational interviewing on women's knowledge about Human Papillomavirus (HPV) infection and their awareness of HPV vaccination. The study will be conducted among women aged 18-45 who have not received the HPV vaccine. Participants in the intervention group will receive structured education and motivational interviews, while the control group will receive no intervention. Changes in HPV knowledge and vaccine awareness will be measured before and after the intervention using validated scales. The goal is to improve preventive behaviors and increase vaccine uptake through behavior-based education.",[26],[60,59,260,261,262,263,264,265],"HPV Vaccine","Health Belief Model","Motivational Interviewing","Vaccine Awareness","Women's Health","Cervical Cancer Prevention","2025-07-24",{"date":268,"type":32},"2025-07-31",{"date":270,"type":22},"2025-08-01",{"date":272,"type":22},"2025-12-01",{"name":274,"class":134},"Saglik Bilimleri Universitesi",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":17,"sex":115,"minAge":282,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":286,"conditions":287,"keywords":292,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":164},"100595727","transmission-of-oncogenic-hpv-infection-among-families-100595727","NCT07036211","Transmission of Oncogenic HPV Infection Among Families","TREVINO","Inclusion Criteria:\n\n* Patient with colposcopy clinic detected persisting HR-HPV infection\n* Patient with diagnosed cervical cancer\n* Patient with diagnosed OSCC\n* Patients' sexual partners of women or men that are referred to the colposcopy\u002Fgynecological oncology\u002FENT\n* offspring (over 12 years old) of the referred couples\n\nExclusion Criteria:\n\n* Candidate who don't speak Finnish","12 Years","100 Years",{"count":285,"type":22},700,"The goal of the Transmission of Oncogenic HPV Infection Among Families (TREVINO) study is to improve understanding of how high-risk human papillomavirus (HPV) infections are transmitted within families. The research focuses on transmission between sexual partners and between parents and children. It also examines how the various microbes may influence the persistence of HPV infections and the development of HPV-related cancers.\n\nThe study will include up to 300 couples recruited from gynecology and ear, nose, and throat (ENT) clinics in Finland, as well as their children. Participants include individuals with persistent HPV infection, cervical precancer or cancer, or HPV-related head and neck cancer, along with their partners and potentially their offspring.\n\nParticipants will provide self-collected samples from the oral and genital areas at multiple time points over up to five years. Questionnaires addressing medical, behavioural, and environmental factors will be completed.\n\nThe study is conducted at Tampere University Hospital and Kuopio University Hospital in Finland. Results will inform HPV screening and prevention programs, improve understanding of family-level transmission, and identify potential microbial and genetic markers linked to cancer risk.",[288,98,289,290,291,26],"Human Papilloma Virus (HPV)","Oropharyngeal Carcinoma","Transmission Vertical","Transmission",[293,294,60],"Oropharyngeal cancer","Cervical cancer","2025-06-16",{"date":297,"type":32},"2025-06-25",{"date":299,"type":22},"2025-08",{"date":301,"type":22},"2031-12",{"name":303,"class":134},"Tampere University Hospital",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":17,"sex":115,"minAge":312,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":316,"conditions":317,"keywords":318,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":40},"100560861","normalizing-antibody-detection-in-first-void-urine-100560861","NCT06582654","Normalizing Antibody Detection in First-void Urine","URINORM: Normalizing Antibody Detection in First-void Urine","URINORM","Inclusion Criteria:\n\n* Vaccinated with either the Cervarix, Gardasil or Gardasil9 HPV-vaccine and able to present vaccination booklet or another official document proving this.\n* Able to understand the information brochure and what the study is about.\n* Willing to give informed consent to contact his\u002Fher general practitioner and\u002For gynecologist to access details on their HPV vaccination schedule and, in case a woman within the screening population, cervical cancer screening results (smears, HPV tests, colposcopy, biopsy).\n\nExclusion Criteria:\n\n* Participating in another clinical trial at the same time of participating in this study.\n* Women that underwent hysterectomy or were treated for cervical (pre)cancer lesions within the six months prior to study enrolment.\n* Pregnant women.\n* Being positive for Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C.\n* Having a history or current evidence of any condition or abnormality that might confound the results of the study or is not in the best interest of the individual to participate, in the opinion of the investigator.","9 Years","70 Years",{"count":315,"type":22},150,"The aim of this study is to develop robust analytical protocols for the monitoring of vaccine induced immunity against the Human Papillomavirus (HPV) in first-void urine samples and to examine fluctuations of urinary HPV-specific antibodies and potential normalization markers in different cohorts.",[26],[319,320,321,322],"Antibodies","Vaccination","Self-sampling","First-void urine","2024-08-30",{"date":325,"type":32},"2024-09-03",{"date":327,"type":32},"2023-12-07",{"date":329,"type":22},"2026-01-01",{"name":331,"class":134},"Universiteit Antwerpen",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":40},"100558963","cervical-cytology-dna-methylation-for-cervical-cancer-screening-100558963","NCT06557954","Cervical Cytology DNA Methylation for Cervical Cancer Screening","Cervical Cytology DNA Methylation for Cervical Cancer Screening: A Real Word Study","Inclusion Criteria:\n\n* Aged 18 years or older\n* With uterine cervix intact\n* Given consents to participate the study\n* With detailed follow-up outcomes\n\nExclusion Criteria:\n\n* Not meeting all of the inclusion criteria",{"count":340,"type":22},30000,"Cervical cancer represents one of the foremost causes of cancer-related morbidity and mortality among women worldwide. Given the current limitations, such as the low specificity of human papillomavirus (HPV) testing and the relatively low sensitivity of cytological examinations, there is a pressing need for a novel, non-invasive, safe, and precise screening method. This study aims to undertake a multicentre, real-world investigation, incorporating at least 10 sub-centres and enrolling 30,000 participants. Histopathological examination results will serve as the 'gold standard' for evaluating the screening efficacy of human PAX1 and JAM3 gene methylation assays (PAX1m\u002FJAM3m), HPV testing, and cytological examinations. Furthermore, the study seeks to elucidate the relationship between DNA methylation levels and persistent HPV infection, while also assessing the applicability of PAX1m\u002FJAM3m across diverse clinical settings. By focusing on alterations in DNA methylation levels within cervical exfoliated cells as the primary research trajectory, this study aspires to furnish novel insights and theoretical foundations for the prevention and management of cervical cancer, targeting PAX1m\u002FJAM3m. The ultimate objective is to facilitate the clinical implementation of an enhanced cervical cancer screening protocol, thereby addressing the deficiencies of current screening methodologies, achieving greater precision in cervical cancer screening, and effectively reducing the incidence of cervical cancer while mitigating the risks of overdiagnosis and overtreatment.",[179,343,344,26,211,345],"DNA Methylation","Cytology","Cancer Screening","2024-08-15",{"date":348,"type":32},"2024-08-19",{"date":350,"type":22},"2024-09-01",{"date":352,"type":22},"2026-10-01",{"name":354,"class":134},"Lei Li"]